The Chocolate Touch Study

The primary objective of the Chocolate Touch study is to demonstrate non-inferior safety and non-inferior effectiveness of the Chocolate Touch™ compared to the Lutonix® drug coated balloon catheter. These data are intended to show safety and effectiveness of the Chocolate Touch sufficient to support regulatory approval to market this device in the United States for use in superficial femoral or popliteal arteries.

Study success is defined as statistical demonstration of the non-inferiority hypothesis tests for both the primary safety and effectiveness hypothesis.

PMA P210039 approval has been granted on 11/04/2022. The study is now in the post-approval phase.

Inclusion criteria

General:

• Minimum of 18 years of age
• Intermittent claudication or ischemic rest pain (Rutherford 2-4)
• Life Expectancy >2 years
• Patient has agreed to follow-up requirements and given informed consent

Angiographic:

• Lesion successfully crossed with a guidewire
• Lesion in the SFA or popliteal artery defined as a lesion with a proximal origin >10 mm from SFA origin (deep femoral artery) and a distal end above the knee joint (at least 3 cm above bottom of the femur - P1).
• Target Lesion ≥70% stenosis in the SFA or popliteal arteries
• Reference Vessel Diameter (RVD) between 4.0 & 6.0mm and within treatment range of Chocolate Touch to be used 1.1:1 at the Target Lesion
• Target Lesion ≤180mm that consists of no more than two adjacent lesions (≤ 25mm apart) and is able to be completely covered with inflation of no more than two assigned balloons (with minimum of >5mm overlap to the area covered by the first balloon). (Note: Adjacent or tandem target lesions must be treated as a single lesion.)
• Angiographic evidence of distal run-off demonstrated by at least one patent tibial vessel without evidence of significant (≥70%) stenosis from origin to ankle
• In-flow vessel without significant stenosis (≥70%) or successful treatment (≤30% residual stenosis with no complications) of a diseased vessel. Note: treatment of contralateral iliac is permissible.

Exclusion criteria

General:

• Acute limb ischemia, or patient indicated for thrombolytic therapy
• Planned surgical or interventional procedures within 30 days after study procedure.
• Non-target lesion concurrent interventions involving a re-entry device, atherectomy, laser, or ablation procedures, the use of a drug eluting stent, or, treatment with any other drug coated balloon.
• Myocardial infarction or stroke within 30 days prior to the procedure
• Known intolerance to required medications, contrast media that cannot be adequately premedicated, nitinol, or Paclitaxel
• Known impaired Renal Function that could have an impact on contrast tolerance with GFR ≤ 30 ml/min per 1.73 m2 and/or elevated serum creatinine >2.5mg/dL (220µmol/L) or on dialysis.
• Known bleeding disorder, or on dialysis, or uncontrolled hypercoagulable disorder
• Non-atherosclerotic lesion (e.g. vasculitis or Berger's disease)
• Female who is pregnant or intends to be pregnant during study
• Patient is enrolled in another investigational clinical study or was previously enrolled in this study

Angiographic:

• Presence of perforation, dissection (Type D or worse) or other injury in target vessel at time of enrollment
• Severe Calcification at the target lesion (defined as angiographic evidence of dense calcification present on both sides of the vessel wall on two orthogonal views and that extends >50 continuous mm in length).
• Previous bypass graft, stent at target vessel (must be greater than 20mm from target lesion), or iliac stent that cannot permit crossing by the treatment balloon within the introducer sheath (Note: In-stent restenosis is not allowed.)